Takeda announces Phase 2/3 IgGNITE study results of investigational subcutaneous TAK-881 in primary immunodeficiency disease at ESID 2026.
Header with Takeda logo and tagline, followed by a split banner featuring press release text and lab imagery. Content body displays title, date, and link, concluding with an alert utility survey and legal footer.
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.
More emails like this
Explore other emails with shared design, campaign, or industry tags.
